Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...
Performances in N.Y.C. Advertisement Supported by A holiday album that cuts through seasonal glut, a late collaboration by Jim McNeely and Helmut Lachenmann’s string quartets are among the highlights.
Complement activation in immunological neurological disorders: mechanisms and therapeutic strategies
Recent advances in the understanding of immune-mediated neurological disorders have led to a paradigm shift toward pathophysiology-directed therapies. Central to this progress is a deeper appreciation ...
Experts at Cincinnati Children's have uncovered striking metabolic differences in people with Fanconi anemia (FA), a rare genetic disorder that causes bone marrow failure and dramatically increases ...
In a highly anticipated article, FDA officials Vinay Prasad, M.D., and Martin Makary, M.D., outlined a novel regulatory pathway that could trigger a seismic shift in how bespoke gene editing therapies ...
Omeros Corporation maintaining a Strong Buy rating after securing a $2.1 billion partnership with Novo Nordisk for MASP-3 inhibitor zaltenibart. OMER's zaltenibart targets Paroxysmal Nocturnal ...
Open-label Phase 2 study shows a single 25 mg COMP360 psilocybin dose was well tolerated, with no serious adverse events observed, and indicated both rapid and durable improvement in symptoms from ...
Patients with type 2 diabetes (T2D) on semaglutide or tirzepatide showed a higher incidence of nonarteritic anterior ischemic optic neuropathy and other optic nerve disorders compared to other ...
Researchers have identified a promising new strategy for treating alcohol use disorder (AUD). A novel study found that the dopamine-boosting drug tolcapone increases activity in the prefrontal cortex ...
New research in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging identifies a novel neural pathway to treat alcohol use disorder. This figure shows areas in which tolcapone, relative to ...
A retrospective cohort study suggested that users of GLP-1 receptor agonists had a 7% higher incidence of new-onset diabetic retinopathy. In patients with existing diabetic retinopathy, use of GLP-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback